TTK Healthcare Ltd
₹ 1,593
-0.83%
26 Apr
- close price
- Market Cap ₹ 2,251 Cr.
- Current Price ₹ 1,593
- High / Low ₹ 1,744 / 1,101
- Stock P/E 34.6
- Book Value ₹ 688
- Dividend Yield 0.63 %
- ROCE 10.1 %
- ROE 99.7 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 104% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 58.7%
- Company has been maintaining a healthy dividend payout of 18.2%
Cons
- The company has delivered a poor sales growth of 4.66% over past five years.
- Earnings include an other income of Rs.58.7 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Diversified Industry: Diversified - Medium / Small
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
354 | 382 | 416 | 483 | 519 | 528 | 578 | 628 | 646 | 476 | 599 | 725 | 752 | |
330 | 362 | 396 | 453 | 478 | 489 | 535 | 578 | 617 | 457 | 577 | 694 | 712 | |
Operating Profit | 24 | 20 | 20 | 30 | 40 | 38 | 43 | 50 | 28 | 19 | 22 | 31 | 40 |
OPM % | 7% | 5% | 5% | 6% | 8% | 7% | 7% | 8% | 4% | 4% | 4% | 4% | 5% |
5 | 7 | 6 | 7 | 6 | 6 | 8 | 8 | 9 | 28 | 42 | 643 | 59 | |
Interest | 3 | 3 | 3 | 4 | 3 | 3 | 5 | 3 | 3 | 2 | 3 | 5 | 3 |
Depreciation | 2 | 3 | 3 | 6 | 7 | 12 | 15 | 15 | 14 | 13 | 13 | 13 | 13 |
Profit before tax | 24 | 22 | 20 | 26 | 36 | 29 | 30 | 39 | 19 | 32 | 48 | 657 | 83 |
Tax % | 34% | 34% | 37% | 39% | 36% | 36% | 40% | 38% | 37% | -44% | 13% | 3% | |
16 | 14 | 12 | 16 | 23 | 19 | 18 | 24 | 12 | 46 | 42 | 640 | 62 | |
EPS in Rs | 20.13 | 18.28 | 15.95 | 20.81 | 29.19 | 24.13 | 12.86 | 17.25 | 8.72 | 32.87 | 29.43 | 452.72 | 43.53 |
Dividend Payout % | 20% | 22% | 25% | 22% | 17% | 21% | 39% | 29% | 34% | 18% | 34% | 2% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 5% |
3 Years: | 4% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | 47% |
5 Years: | 104% |
3 Years: | 273% |
TTM: | 128% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 19% |
3 Years: | 37% |
1 Year: | 27% |
Return on Equity | |
---|---|
10 Years: | 35% |
5 Years: | 44% |
3 Years: | 59% |
Last Year: | 100% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Reserves | 80 | 90 | 99 | 110 | 128 | 150 | 219 | 237 | 235 | 281 | 316 | 939 | 958 |
18 | 22 | 32 | 42 | 38 | 23 | 47 | 29 | 30 | 19 | 22 | 27 | 25 | |
86 | 89 | 102 | 115 | 128 | 104 | 127 | 136 | 152 | 180 | 207 | 189 | 185 | |
Total Liabilities | 192 | 209 | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,170 | 1,182 |
33 | 43 | 54 | 52 | 106 | 99 | 110 | 98 | 89 | 85 | 80 | 71 | 77 | |
CWIP | 6 | 0 | 2 | 46 | 1 | 0 | 1 | 2 | 9 | 0 | 0 | 3 | 2 |
Investments | 7 | 1 | 0 | 0 | 10 | 9 | 9 | 13 | 9 | 13 | 15 | 13 | 14 |
146 | 165 | 184 | 177 | 185 | 177 | 288 | 304 | 325 | 395 | 463 | 1,083 | 1,090 | |
Total Assets | 192 | 209 | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,170 | 1,182 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
6 | 24 | 13 | 39 | 37 | 18 | 25 | 17 | 20 | 96 | 45 | -26 | |
-4 | -1 | -15 | -49 | -27 | 5 | -22 | 10 | -13 | -77 | -30 | 33 | |
-1 | -2 | 2 | 3 | -11 | -23 | -7 | -31 | -10 | -17 | -10 | -12 | |
Net Cash Flow | 1 | 22 | 0 | -7 | -0 | 0 | -4 | -4 | -4 | 2 | 5 | -6 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 39 | 34 | 34 | 34 | 33 | 24 | 35 | 47 | 43 | 46 | 33 | 46 |
Inventory Days | 64 | 52 | 64 | 62 | 66 | 65 | 80 | 77 | 101 | 123 | 102 | 89 |
Days Payable | 70 | 55 | 56 | 50 | 53 | 100 | 130 | 101 | 121 | 170 | 134 | 131 |
Cash Conversion Cycle | 32 | 31 | 41 | 46 | 46 | -11 | -16 | 22 | 23 | -2 | 1 | 4 |
Working Capital Days | 1 | -8 | -12 | -14 | -22 | -9 | -1 | 10 | 13 | -18 | -15 | 17 |
ROCE % | 27% | 21% | 17% | 20% | 23% | 18% | 15% | 15% | 8% | 6% | 8% | 10% |
Documents
Announcements
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 22 Apr
- Compliance Certificate Under Regulation 40(9) Of The SEBI (LODR) Regulations, 2015, For The Year Ended 31St March, 2024 11 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 8 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 2 Apr
- Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 2 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Sep 2016TranscriptNotesPPT
Pharmaceuticals Business
The company's pharmaceuticals business includes products for both human and veterinary use: